TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area of Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response (SVR) against HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Awake Objective Cough Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral feeding readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiologic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of significant changes in heart rate (bradycardia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Popliteal Angle Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes of Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of knee Range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shifts in pressure distribution over seated pressure points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of additional disease and/or change in extent of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Calcification (Presence and Degree as Measured by Agatston Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects who selected or purchased gabapentin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subject compliance with directions for use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of β-TG, F1+2 and TAT in shed blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: peripheral nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score on Pelvic Exam Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Karolinska Sleepiness Scale score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: % Loss renal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite Opioid Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of asymptomatic and symptomatic cardiac dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of reversible cardiac function decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Survival Rate at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Area Under The Serum Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical relapse-free survival (cRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Self-Reported Quality Of Life Changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma concentration-time curve from time zero to time t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of Olaparib treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Retained
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Participants Virally Suppressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Neck discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Nelfinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: value of E and A peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral blood flow abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drinks preceding week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy drinking days preceding week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth rate of height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Growth rate of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Growth rate of head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coronary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in coronary resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: User Performance (UP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Accuracy (SA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sexual Dysfunction Inventory Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression-free Survival (PFS) per RECIST v1.1 Criteria
Endpoint domain: Mortality/survival
Primary endpoint: Global disability assessed via the modified Rankin score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Participant Retention Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apgar index of the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days required to get a positive COVID-19 PCR to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptoms progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of graft loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Ischemic Type Biliary Lesions (ITBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: disposition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: insulinogenic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hepatic insulin extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: patient satisfaction with treatment and result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in ADHD Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with acute GVHD at day 100 post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Primary Assisted Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom From Target Lesion Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With One or More Device- or Procedure-related Serious Adverse Events and Deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Stent Fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Brain MRI microstructural/functional alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain MRI metabolic alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levodopa equivalent daily dosage (LEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolving signs and symptoms of perianal dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peak Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage time spent with SVV < 13%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance for Early infant diagnosis (EID) of HIV
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early identification of HEI at Reproductive and Child Health (RCH) Clinic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antenatal care (ANC) visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Facility delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post natal care (PNC) visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nevirapine (NVP) at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Picture Naming Abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in soluble hemojuvelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in other indices of iron metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length-for-age z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment after non-myeloablative HSC transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Pain Interference 6b
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Opioid Risk Tool
Endpoint domain: Adverse events/effects
Primary endpoint: PROMIS Short Form v1.0-Prescription Pain Medication Misuse
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Maintaining HCV RNA Load Below LOQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concordance between MET diagnosis and definitive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent Change of Active Blisters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total Blister/Erosion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Change of Disabilities of Arm, Shoulder and Hand Score (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Pain on visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Menstrual Cycle Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Onychomycosis severity index (OSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut microbial community structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean total SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Response to Bortezomib Measured by Parathyroid Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Positive Response to Bortezomib Measured by Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive Response to Bortezomib Measured by Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive Response to Bortezomib Measured by Magnesium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive Response to Bortezomib Measured by Phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numerical Pain Ranking Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for swallowing the tethered capsule endoscope (TCE) to the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of images obtained in the entire TCE procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall comfort during ingestion, pullback, and withdrawal of the TCE
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shift in the mRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Economic productivity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of partnered relationships
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rates of child abuse and neglect
Endpoint domain: Adverse events/effects
Primary endpoint: Change from BOMP (Bleeding on Marginal Probing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia/Nociception Index (ANI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores on a 0-10 Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline on modified Roland-Morris Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference of sitting diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to reach Maximum plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic measures (Cmax, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numerical Pain Scores (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Totelle 1mg
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Totelle 1mg
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic yield of a subsegmental pulmonary lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful shoulder reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Operation of RLN monitoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Grade 3-4 Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: percentages of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of residual grafted material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of marrow spaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Undetectable PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alleviation of breakthrough pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Match between gastral aspirate PCR results and urine PCR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demonstrate Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Dix Hall Pike Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fukuda Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motion Sensitivity Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who develop antibodies to rAAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Eyes With Absolute Value of Intraocular (IOL) Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total number of intrusions following the first trauma movie exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of intrusions following the second trauma movie exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the diameter of retinal blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Continuous blood glucose profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Attendance of the Fit & Strong! Intervention Classes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Fit & Strong! Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: degree of peripheral neuropathy based on PQAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: degree of distress based on NCCN-DT
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: degree of peripheral neuropathy based on MSNI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: degree of peripheral neuropathy based on CTCAE grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perfusion of Burned Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive Free Survival Post Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Chromosome aberration in peripheral blood lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pruritis intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change in UPDRS Scores - Motor Section (Part III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with abnormal vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal laboratory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of large gaps in the delayed enhancement MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generic Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inducible myocardial ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Density of the macular pigment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mTOR inhibitor effects on endometrial tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes